Next Article in Journal
Optimizing Paclitaxel Oral Absorption and Bioavailability: TPGS Co-Coating via Supercritical Anti-Solvent Fluidized Bed Technology
Next Article in Special Issue
Correction: Awad et al. Repurposing Potential of the Antiparasitic Agent Ivermectin for the Treatment and/or Prophylaxis of COVID-19. Pharmaceuticals 2022, 15, 1068
Previous Article in Journal
Synthesis, In Vitro Biological Evaluation and Molecular Modeling of Benzimidazole-Based Pyrrole/Piperidine Hybrids Derivatives as Potential Anti-Alzheimer Agents
Previous Article in Special Issue
Repurposing Potential of the Antiparasitic Agent Ivermectin for the Treatment and/or Prophylaxis of COVID-19
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 17
Issue 4
10.3390/ph17040411
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Pharmaceuticals 2020, 13(6), 132.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Palmeira et al. Preliminary Virtual Screening Studies to Identify GRP78 Inhibitors Which May Interfere with SARS-CoV-2 Infection. Pharmaceuticals 2020, 13, 132

by
Andreia Palmeira
1,2,
Emília Sousa
1,2,
Aylin Köseler
3,*,
Ramazan Sabirli
4,
Tarık Gören
5,
İbrahim Türkçüer
5,
Özgür Kurt
6,
Madalena M. Pinto
1,2 and
M. Helena Vasconcelos
7,8,9,*
1
Laboratory of Organic and Pharmaceutical Chemistry (LQOF), Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal
2
Interdisciplinary Centre of Marine and Environmental Research (CIIMAR), 4450-208 Matosinhos, Portugal
3
Department of Biophysics, Pamukkale University Faculty of Medicine, 20190 Denizli, Turkey
4
Department of Emergency Medicine, Kafkas University Faculty of Medicine, 36000 Kars, Turkey
5
Department of Emergency Medicine, Pamukkale University Faculty of Medicine, 20190 Denizli, Turkey
6
Department of Microbiology, Acibadem Mehmet Ali Aydinlar University School of Medicine, 34752 Istanbul, Turkey
7
Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, 4200-135 Porto, Portugal
8
Cancer Drug Resistance Group, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), 4200-135 Porto, Portugal
9
Laboratory of Microbiology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
*
Authors to whom correspondence should be addressed.
Pharmaceuticals 2024, 17(4), 411; https://doi.org/10.3390/ph17040411
Submission received: 8 February 2024 / Accepted: 27 February 2024 / Published: 25 March 2024
(This article belongs to the Special Issue COVID-19 in Pharmaceuticals)
Versions Notes

Text Correction

There was an error in the original publication. In the introduction of the paper [1], GRP78 was incorrectly also named as Byun1.
A correction has been made to Introduction, third paragraph:
Glucose Regulated Protein 78 (GRP78), also known as Binding immunoglobulin protein (BiP) or heat shock 70 kDa protein 5 (HSPA5), is a HSP70 molecular chaperone encoded by the HSPA5 gene.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Palmeira, A.; Sousa, E.; Köseler, A.; Sabirli, R.; Gören, T.; Türkçüer, İ.; Kurt, Ö.; Pinto, M.M.; Vasconcelos, M.H. Preliminary Virtual Screening Studies to Identify GRP78 Inhibitors Which May Interfere with SARS-CoV-2 Infection. Pharmaceuticals 2020, 13, 132. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Palmeira, A.; Sousa, E.; Köseler, A.; Sabirli, R.; Gören, T.; Türkçüer, İ.; Kurt, Ö.; Pinto, M.M.; Vasconcelos, M.H. Correction: Palmeira et al. Preliminary Virtual Screening Studies to Identify GRP78 Inhibitors Which May Interfere with SARS-CoV-2 Infection. Pharmaceuticals 2020, 13, 132. Pharmaceuticals 2024, 17, 411. https://doi.org/10.3390/ph17040411

AMA Style

Palmeira A, Sousa E, Köseler A, Sabirli R, Gören T, Türkçüer İ, Kurt Ö, Pinto MM, Vasconcelos MH. Correction: Palmeira et al. Preliminary Virtual Screening Studies to Identify GRP78 Inhibitors Which May Interfere with SARS-CoV-2 Infection. Pharmaceuticals 2020, 13, 132. Pharmaceuticals. 2024; 17(4):411. https://doi.org/10.3390/ph17040411

Chicago/Turabian Style

Palmeira, Andreia, Emília Sousa, Aylin Köseler, Ramazan Sabirli, Tarık Gören, İbrahim Türkçüer, Özgür Kurt, Madalena M. Pinto, and M. Helena Vasconcelos. 2024. "Correction: Palmeira et al. Preliminary Virtual Screening Studies to Identify GRP78 Inhibitors Which May Interfere with SARS-CoV-2 Infection. Pharmaceuticals 2020, 13, 132" Pharmaceuticals 17, no. 4: 411. https://doi.org/10.3390/ph17040411

APA Style

Palmeira, A., Sousa, E., Köseler, A., Sabirli, R., Gören, T., Türkçüer, İ., Kurt, Ö., Pinto, M. M., & Vasconcelos, M. H. (2024). Correction: Palmeira et al. Preliminary Virtual Screening Studies to Identify GRP78 Inhibitors Which May Interfere with SARS-CoV-2 Infection. Pharmaceuticals 2020, 13, 132. Pharmaceuticals, 17(4), 411. https://doi.org/10.3390/ph17040411

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop